RYAH Group Inc. (CSE: RYAH) Cannabis Clinical Trials Improve Due to Dose-Measuring Devices

  • Cannabis is a chemically variable plant making its clinical trials problematic, before the creation of dose-measuring devices
  • RYAH Smart inhalers being used in one of the largest clinical studies of its kind focused on chronic pain 
  • Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating

Regulating dose size in cannabis clinical trials has proven problematic from one test subject to another because cannabis is a chemically variable plant. RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics, allowing for more control for variables within a clinical setting. 

In a recent article, RYAH outlined the history of cannabis clinical trials compared to how they are conducted in 2021. The full report can be found at https://ibn.fm/wwPrP.

It’s interesting to note that most cannabis studies have been anti-cannabis, focusing on cannabis-related crime, intoxication/abuse, and use among adolescents until recently. Instead of looking to this plant for its medicinal benefits, the focus has been on its potentially harmful effects. Today, research teams are exploring the use of cannabis to address chronic conditions, especially for pain relief. In the past, studying the plant was complex and controlling dose size and strain profile problematic.

In 2019, RYAH began commercializing its smart inhaler solution. Since then, it has created an ecosystem of IoT products, each with three elements: dose-measuring device, medicine-carrying component and a mobile application. The Smart inhaler is the first dry-herb inhaler of its kind where the user can track and control the amount inhaled. This allows for more consistent and predictable results. The connected Health App allows for stat-tracking and presets for both temperatures and dosing, both of which can be adjusted to the user’s needs. The collection of the data provides for efficacy analysis and adjustments to future treatments. 

RYAH has begun to work with an international oncology clinic in the UK on one of the largest clinical trials of its kind. The company will be studying the safety and efficacy of cannabis and hemp for the treatment of chronic pain. Recently the company successfully shipped 10,000 dry-herb cartridges and QR codes in its initial shipment for the clinic’s pilot run. The complete order includes potentially thousands of RYAH Smart inhalers and millions of proprietary cartridges for the use of this study over the next five years.

The future for cannabis study with the addition of dose-measuring devices looks promising. RYAH has found over 400 studies on cannabis that are currently in the recruitment or study phase in the U.S., with more in Canada, the U.K., and Israel. The plant’s many therapeutic benefits are finally being explored, and the potential for creating better treatment plans for patients with various medical conditions is high. 

Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating. As the perception of cannabis changes in the public eye, so do the opportunities for developing more clinical trials focused on this plant’s therapeutic potential. 

To learn more about this company, visit  www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050